[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"trial:NCT06843447":3,"trial-entities:NCT06843447":471,"trial-summary:NCT06843447":477},{"id":4,"nct_id":4,"org_study_id":5,"brief_title":6,"official_title":7,"overall_status":8,"completion_date":9,"status_verified_date":10,"last_update_date":11,"start_date":12,"sponsor_name":13,"lead_sponsor_class":14,"has_dmc":15,"brief_summary":16,"detailed_description":17,"conditions":18,"keywords":20,"study_type":21,"primary_purpose":22,"phases":23,"enrollment_info":26,"interventions":29,"primary_outcomes":86,"secondary_outcomes":101,"sex":118,"minimum_age":119,"maximum_age":120,"healthy_volunteers":15,"eligibility_criteria":121,"std_ages":150,"locations":153,"central_contacts":457,"overall_officials":462,"references":466,"see_also_links":467},"NCT06843447","5909-003","A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)","A Phase 1b\u002F2 Open-label, Multicenter Study to Evaluate the Safety and Efficacy of Raludotatug Deruxtecan With or Without Other Anticancer Investigational Agents in Participants With High-grade Serous Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer Who Have Relapsed After Prior Platinum-based Chemotherapy","RECRUITING","2029-03-27","2026-08","2026-08-14","2025-04-15","Merck Sharp & Dohme LLC","INDUSTRY",false,"Researchers are looking for other ways to treat relapsed high-grade serous ovarian cancer. Relapsed means the cancer came back after treatment. High-grade means the cancer cells grow and spread quickly. Serous means the cancer started in the cells that cover the ovaries, the lining of the belly, or in the fallopian tubes.\n\nStandard treatment (usual treatment) for people with relapsed high-grade serous ovarian cancer may include:\n\n* Chemotherapy, which is a treatment that uses medicine to destroy cancer cells or stop them from growing\n* Targeted therapy, which is a treatment that works to control how specific types of cancer cells grow and spread\n\nRaludotatug deruxtecan (R-DXd) is a study treatment that is an antibody drug conjugate (ADC). An ADC attaches to a protein on cancer cells and delivers treatment to destroy those cells. Researchers want to know if R-DXd is safe to take with other treatments and if people tolerate them together. They also want to learn how many people have the cancer respond (gets smaller or goes away) to the treatments.","This study has 2 parts: Part 1 is a dose escalation phase of R-DXd. Part 2 is the expansion phase and will use the Recommended Phase 2 Dose (RP2D) of R-DXd determined in Part 1.",[19],"Ovarian Cancer Recurrent",[],"INTERVENTIONAL","TREATMENT",[24,25],"PHASE1","PHASE2",{"count":27,"type":28},460,"ESTIMATED",[30,46,52,55,68,72,76,80],{"type":31,"name":32,"description":33,"armGroupLabels":34,"otherNames":44},"BIOLOGICAL","Raludotatug Deruxtecan","IV infusion on Day 1 of every 3-week cycle.",[35,36,37,38,39,40,41,42,43],"Cohort A-1 Arm 1 (R-DXd + Carboplatin Dose 1)","Cohort A-1 Arm 2 (R-DXd + Paclitaxel)","Cohort A-1 Arm 3 (R-DXd + Carboplatin Dose 2)","Cohort A-2 Arm 1 (R-DXd RP2D + Carboplatin +\u002F- Bevacizumab)","Cohort A-2 Arm 2 (R-DXd RP2D + Paclitaxel +\u002F- Bevacizumab)","Cohort B-1 (R-DXd + Bevacizumab)","Cohort B-2 (R-DXd RP2D + Bevacizumab)","Cohort C-1 (R-DXd + Pembrolizumab)","Cohort D (R-DXd RP2D +\u002F- Bevacizumab)",[45],"MK-5909, R-DXd",{"type":47,"name":48,"description":49,"armGroupLabels":50},"DRUG","Carboplatin","IV infusion on Day 1 of every 3-week cycle for a maximum of 6 cycles.",[35,37,38,51],"Cohort A-2 Arm 3 (Platinum-Based Doublet Chemotherapy +\u002F- Bevacizumab)",{"type":47,"name":53,"description":49,"armGroupLabels":54},"Paclitaxel",[36,39,51],{"type":31,"name":56,"description":33,"armGroupLabels":57,"otherNames":58},"Bevacizumab",[38,39,51,40,41,43],[59,60,61,62,63,64,65,66,67],"Includes, based on sourcing:","- Avastin®","- Alymsys®","- MVASI®","- Oyavas®","- Zirabev®","- Vegzelma®","- Aybintio®","- Breztri®",{"type":47,"name":69,"description":70,"armGroupLabels":71},"Rescue Medication","Includes 5-HT3 Serotonin Receptor Antagonist, NK-1 receptor antagonist, and corticosteroid, administered per protocol.",[35,36,37,38,39,40,41,42,43],{"type":31,"name":73,"description":74,"armGroupLabels":75},"Pembrolizumab","IV infusion on Day 1 of every 3-week cycle for a maximum of 35 cycles.",[42],{"type":47,"name":77,"description":78,"armGroupLabels":79},"Gemcitabine","IV injection on days 1 and 8 of each 3-week Cycle",[51],{"type":47,"name":81,"description":82,"armGroupLabels":83,"otherNames":84},"Pegylated liposomal doxorubicin","IV injection administered on Day 1 of each 4-week cycle",[51],[85],"PLD",[87,91,95,98],{"measure":88,"description":89,"timeFrame":90},"Part 1: Number of Participants Who Experience a Dose-limiting Toxicity (DLT) Per Common Terminology Criteria for Adverse Events, Version 5.0 (CTCAE v5.0)","DLTs are defined as toxicities during the DLT evaluation period that are assessed by the investigator to be possibly, probably, or definitely related to study treatment and include: Grade 4 thrombocytopenia of any duration or Grade 3 thrombocytopenia lasting ≥7 days; Grade 3 or higher thrombocytopenia associated with clinically significant bleeding; Grade 4 lymphocytopenia lasting ≥14 days; Grade 4 anemia of any duration; any other Grade 4 hematologic toxicity lasting ≥7 days; febrile neutropenia Grade 3 or Grade 4 meeting pre-specifications; pre-specified hepatic organ toxicities; all Grade 3 or higher other nonhematologic toxicities except those pre-specified; other pre-specified nonhematologic toxicities; any delay in treatment with the planned dose of ≥21 days or discontinuation of treatment due to a toxicity during the DLT evaluation period, or Grade 5 toxicity. The number of participants with DLTs will be reported.","Up to 21 days",{"measure":92,"description":93,"timeFrame":94},"Part 1: Number of Participants with One or More Adverse Events (AEs)","An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants with one or more AEs will be reported.","Up to approximately 3 years",{"measure":96,"description":97,"timeFrame":94},"Part 1: Number of Participants who Discontinue Study Intervention Due to an AE","An AE is any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. The number of participants who discontinue study intervention due to an AE will be reported.",{"measure":99,"description":100,"timeFrame":94},"Part 2: Objective Response Rate (ORR)","ORR is defined as the percentage of participants with Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1). The percentage of participants who experience CR or PR as assessed by Blinded Independent Central Review (BICR) will be presented.",[102,105,108,111,114,116],{"measure":103,"description":104,"timeFrame":94},"Part 1: Objective Response Rate (ORR)","ORR is defined as the percentage of participants who have a confirmed Complete Response (CR: Disappearance of all target lesions) or a Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria In Solid Tumours version 1.1 (RECIST 1.1). ORR will be assessed by blinded independent central review (BICR).",{"measure":106,"description":107,"timeFrame":94},"Part 2: Duration of Response (DOR)","For participants who demonstrate a confirmed Complete Response (CR: disappearance of all target lesions) or Partial Response (PR: at least a 30% decrease in the sum of diameters of target lesions) per Response Evaluation Criteria In Solid Tumors Version 1.1 (RECIST 1.1), DOR is defined as the time from first documented evidence of CR or PR until progressive disease (PD) or death. Per RECIST 1.1, PD is defined as at least a 20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. The appearance of one or more new lesions is also considered PD. DOR as assessed by Blinded Independent Central Review (BICR) will be presented.",{"measure":109,"description":110,"timeFrame":94},"Part 2: Progression-free Survival (PFS)","PFS is defined as the time from randomization to the first documented progressive disease (PD) or death due to any cause, whichever occurs first as assessed by Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1). PD is defined as ≥20% increase in the sum of diameters of target lesions. In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of ≥5 mm. The appearance of one or more new lesions is also considered PD. PFS as assessed by blinded independent central review (BICR) will be presented.",{"measure":112,"description":113,"timeFrame":94},"Part 2: Overall Survival (OS)","OS is defined as the time from the first dose of study treatment to death due to any cause.",{"measure":115,"description":97,"timeFrame":94},"Part 2: Number of Participants with One or More AEs",{"measure":117,"description":97,"timeFrame":94},"Part 2: Number of Participants who Discontinue Study Intervention Due to an AE","FEMALE","18 Years",null,{"inclusion":122,"exclusion":135,"raw_text":149},[123,124,125,126,127,128,129,130,131,132,133,134],"Has pathologically documented diagnosis of high-grade serous epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer","Has measurable disease per Response Evaluation Criteria In Solid Tumors 1.1","Participants in Cohort A-1 Arms 2 and 3: Has relapsed disease after 1 to 3 prior lines of therapy and radiographic evidence of disease progression ≥6 months (≥180 days) after the last dose of platinum-based therapy (ie, platinum-sensitive disease)","Participants in Cohort B-1 and Cohort B-2: Has relapsed disease after 1 to 3 prior lines of therapy and radiographic evidence of disease progression \\\u003C6 months (\\\u003C180 days) after the last dose of platinum-based therapy (ie, platinum-resistant disease). Participants must have received no more than 1 prior bevacizumab-containing systemic treatment regimen","Participants in Cohort B-1 and Cohort B-2: Is a candidate for bevacizumab treatment","Has provided tumor tissue from a core or excisional biopsy of a tumor lesion not previously irradiated","Has an Eastern Cooperative Oncology Group performance status of 0 to 1 assessed within 7 days before allocation\u002Frandomization","Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on anti-retroviral therapy","Participants who are hepatitis B surface antigen positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks, and have undetectable HBV viral load prior to allocation\u002Frandomization","Participants with a history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening","Participants in Cohort C-1 and Cohort D: Has relapsed disease after 1 prior line of therapy, radiographic evidence of disease progression ≥6 months (≥180 days) after the last dose of platinum-based therapy (ie, platinum-sensitive disease) and progressed during prior treatment with PARPi in the first-line setting","Cohort A-2 Arms 1, 2, and 3: Has relapsed disease after 1 prior line of therapy and radiographic evidence of disease progression ≥6 months (≥180 days) after the last dose of platinum-based therapy (ie, platinum-sensitive disease)",[136,137,138,139,140,141,142,143,144,145,146,147,148],"Has any of the following within 6 months before allocation\u002Frandomization: cerebrovascular accident, transient ischemic attack, or other arterial thromboembolic event","Has uncontrolled or significant cardiovascular disease","Has clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder, and any autoimmune, connective tissue, or inflammatory disorders with potential pulmonary involvement, or prior pneumonectomy","Has ≥Grade 2 peripheral neuropathy","Has received prior treatment with cadherin-6-targeted agents","Has received prior systemic anticancer therapy including investigational agents within 4 weeks or 5 half-lives (whichever is shorter) before allocation","Has received prior radiotherapy within 2 weeks of the start of study intervention, or has radiation-related toxicities, requiring corticosteroids","Receives chronic steroid treatment","Has known additional malignancy that is progressing or has required active treatment within the past 3 years","Has known active CNS metastases and\u002For carcinomatous meningitis","Has any history of interstitial lung disease (ILD)\u002Fpneumonitis irrespective of prior steroid use, current ILD, or suspected ILD, or ILD that cannot be ruled out by imaging at screening","Has active infection requiring systemic therapy","HIV-infected participants with a history of Kaposi's sarcoma and\u002For Multicentric Castleman's Disease","Inclusion Criteria:\n\n* Has pathologically documented diagnosis of high-grade serous epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer\n* Has measurable disease per Response Evaluation Criteria In Solid Tumors 1.1\n* Participants in Cohort A-1 Arms 2 and 3: Has relapsed disease after 1 to 3 prior lines of therapy and radiographic evidence of disease progression ≥6 months (≥180 days) after the last dose of platinum-based therapy (ie, platinum-sensitive disease)\n* Participants in Cohort B-1 and Cohort B-2: Has relapsed disease after 1 to 3 prior lines of therapy and radiographic evidence of disease progression \\\u003C6 months (\\\u003C180 days) after the last dose of platinum-based therapy (ie, platinum-resistant disease). Participants must have received no more than 1 prior bevacizumab-containing systemic treatment regimen\n* Participants in Cohort B-1 and Cohort B-2: Is a candidate for bevacizumab treatment\n* Has provided tumor tissue from a core or excisional biopsy of a tumor lesion not previously irradiated\n* Has an Eastern Cooperative Oncology Group performance status of 0 to 1 assessed within 7 days before allocation\u002Frandomization\n* Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on anti-retroviral therapy\n* Participants who are hepatitis B surface antigen positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks, and have undetectable HBV viral load prior to allocation\u002Frandomization\n* Participants with a history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable at screening\n* Participants in Cohort C-1 and Cohort D: Has relapsed disease after 1 prior line of therapy, radiographic evidence of disease progression ≥6 months (≥180 days) after the last dose of platinum-based therapy (ie, platinum-sensitive disease) and progressed during prior treatment with PARPi in the first-line setting\n* Cohort A-2 Arms 1, 2, and 3: Has relapsed disease after 1 prior line of therapy and radiographic evidence of disease progression ≥6 months (≥180 days) after the last dose of platinum-based therapy (ie, platinum-sensitive disease)\n\nExclusion Criteria:\n\n* Has any of the following within 6 months before allocation\u002Frandomization: cerebrovascular accident, transient ischemic attack, or other arterial thromboembolic event\n* Has uncontrolled or significant cardiovascular disease\n* Has clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder, and any autoimmune, connective tissue, or inflammatory disorders with potential pulmonary involvement, or prior pneumonectomy\n* Has ≥Grade 2 peripheral neuropathy\n* Has received prior treatment with cadherin-6-targeted agents\n* Has received prior systemic anticancer therapy including investigational agents within 4 weeks or 5 half-lives (whichever is shorter) before allocation\n* Has received prior radiotherapy within 2 weeks of the start of study intervention, or has radiation-related toxicities, requiring corticosteroids\n* Receives chronic steroid treatment\n* Has known additional malignancy that is progressing or has required active treatment within the past 3 years\n* Has known active CNS metastases and\u002For carcinomatous meningitis\n* Has any history of interstitial lung disease (ILD)\u002Fpneumonitis irrespective of prior steroid use, current ILD, or suspected ILD, or ILD that cannot be ruled out by imaging at screening\n* Has active infection requiring systemic therapy\n* HIV-infected participants with a history of Kaposi's sarcoma and\u002For Multicentric Castleman's Disease",[151,152],"ADULT","OLDER_ADULT",[154,168,179,190,201,211,222,233,241,252,263,275,282,293,303,313,323,335,343,353,364,373,380,387,397,409,420,429,440,447],{"facility":155,"status":8,"city":156,"state":157,"zip":158,"country":159,"contacts":160,"geoPoint":165},"Yale-New Haven Hospital-Smilow Cancer Hospital at Yale-New Haven ( Site 0019)","New Haven","Connecticut","06510","United States",[161],{"name":162,"role":163,"phone":164},"Study Coordinator","CONTACT","203-785-2404",{"lat":166,"lon":167},41.30815,-72.92816,{"facility":169,"status":8,"city":170,"state":171,"zip":172,"country":159,"contacts":173,"geoPoint":176},"The University of Louisville, James Graham Brown Cancer Center ( Site 0009)","Louisville","Kentucky","40202",[174],{"name":162,"role":163,"phone":175},"502-562-3429",{"lat":177,"lon":178},38.25424,-85.75941,{"facility":180,"status":8,"city":181,"state":182,"zip":183,"country":159,"contacts":184,"geoPoint":187},"TRIALS 365 ( Site 0020)","Shreveport","Louisiana","71103",[185],{"name":162,"role":163,"phone":186},"318-408-1198",{"lat":188,"lon":189},32.52515,-93.75018,{"facility":191,"status":8,"city":192,"state":193,"zip":194,"country":159,"contacts":195,"geoPoint":198},"Dana-Farber Cancer Institute ( Site 0015)","Boston","Massachusetts","02215",[196],{"name":162,"role":163,"phone":197},"877-338-7425",{"lat":199,"lon":200},42.35843,-71.05977,{"facility":202,"status":8,"city":203,"state":203,"zip":204,"country":159,"contacts":205,"geoPoint":208},"Memorial Sloan Kettering Cancer Center ( Site 0003)","New York","10065",[206],{"name":162,"role":163,"phone":207},"212-639-2000",{"lat":209,"lon":210},40.71427,-74.00597,{"facility":212,"status":8,"city":213,"state":214,"zip":215,"country":159,"contacts":216,"geoPoint":219},"OU Health University of Oklahoma Medical Center ( Site 7000)","Oklahoma City","Oklahoma","73104",[217],{"name":162,"role":163,"phone":218},"405-271-1112",{"lat":220,"lon":221},35.46756,-97.51643,{"facility":223,"status":8,"city":224,"state":225,"zip":226,"country":159,"contacts":227,"geoPoint":230},"Texas Oncology - DFW ( Site 8000)","Fort Worth","Texas","76104",[228],{"name":162,"role":163,"phone":229},"615-329-7430",{"lat":231,"lon":232},32.72541,-97.32085,{"facility":234,"status":235,"city":236,"state":225,"zip":237,"country":159,"geoPoint":238},"Houston Methodist Hospital ( Site 0010)","COMPLETED","Houston","77030",{"lat":239,"lon":240},29.76328,-95.36327,{"facility":242,"status":8,"city":243,"state":244,"zip":245,"country":159,"contacts":246,"geoPoint":249},"START Mountain Region ( Site 0008)","West Valley City","Utah","84119",[247],{"name":162,"role":163,"phone":248},"801-907-4750",{"lat":250,"lon":251},40.69161,-112.00105,{"facility":253,"status":8,"city":254,"state":255,"zip":256,"country":159,"contacts":257,"geoPoint":260},"University of Virginia Health System ( Site 0011)","Charlottesville","Virginia","22908",[258],{"name":162,"role":163,"phone":259},"434-924-9333",{"lat":261,"lon":262},38.02931,-78.47668,{"facility":264,"status":8,"city":265,"state":266,"zip":267,"country":268,"contacts":269,"geoPoint":272},"Centre Hospitalier de l'Université de Montréal ( Site 0102)","Montreal","Quebec","H2X 0A9","Canada",[270],{"name":162,"role":163,"phone":271},"514-890-8000",{"lat":273,"lon":274},45.50884,-73.58781,{"facility":276,"status":8,"city":265,"state":266,"zip":277,"country":268,"contacts":278,"geoPoint":281},"McGill University Health Centre ( Site 0100)","H4A 3J1",[279],{"name":162,"role":163,"phone":280},"514-934-1934x31975",{"lat":273,"lon":274},{"facility":283,"status":8,"city":284,"zip":285,"country":286,"contacts":287,"geoPoint":290},"Rambam Health Care Campus ( Site 0202)","Haifa","3109601","Israel",[288],{"name":162,"role":163,"phone":289},"972-4-7776234",{"lat":291,"lon":292},32.81303,34.99928,{"facility":294,"status":8,"city":295,"zip":296,"country":286,"contacts":297,"geoPoint":300},"Shaare Zedek Medical Center ( Site 0201)","Jerusalem","9103102",[298],{"name":162,"role":163,"phone":299},"+972-(0)2-6555424",{"lat":301,"lon":302},31.76904,35.21633,{"facility":304,"status":8,"city":305,"zip":306,"country":286,"contacts":307,"geoPoint":310},"Rabin Medical Center ( Site 0203)","Petah Tikva","4941492",[308],{"name":162,"role":163,"phone":309},"+97239378076",{"lat":311,"lon":312},32.08707,34.88747,{"facility":314,"status":8,"city":315,"zip":316,"country":286,"contacts":317,"geoPoint":320},"Sheba Medical Center ( Site 0200)","Ramat Gan","5265601",[318],{"name":162,"role":163,"phone":319},"972-3-5304498",{"lat":321,"lon":322},32.08227,34.81065,{"facility":324,"status":8,"city":325,"state":326,"zip":327,"country":328,"contacts":329,"geoPoint":332},"Institut Català d'Oncologia - L'Hospitalet ( Site 0302)","L'Hospitalet de Llobregat","Barcelona","08908","Spain",[330],{"name":162,"role":163,"phone":331},"+34932607744",{"lat":333,"lon":334},41.35967,2.10028,{"facility":336,"status":8,"city":337,"state":338,"zip":339,"country":328,"contacts":340},"HOSPITAL UNIVERSITARIO PUERTA DE HIERRO MAJADAHONDA ( Site 0307)","Majadhonda","Madrid","28222",[341],{"name":162,"role":163,"phone":342},"+34 911917358",{"facility":344,"status":8,"city":338,"state":345,"zip":346,"country":328,"contacts":347,"geoPoint":350},"Clinica Universidad de Navarra ( Site 0301)","Madrid, Comunidad de","28027",[348],{"name":162,"role":163,"phone":349},"+349135319207513",{"lat":351,"lon":352},40.4165,-3.70256,{"facility":354,"status":8,"city":355,"state":356,"zip":357,"country":328,"contacts":358,"geoPoint":361},"Hospital General Universitario de Valencia ( Site 0305)","Valencia","Valenciana, Comunitat","46014",[359],{"name":162,"role":163,"phone":360},"+34 963187527",{"lat":362,"lon":363},39.47391,-0.37966,{"facility":365,"status":8,"city":326,"zip":366,"country":328,"contacts":367,"geoPoint":370},"Hospital Universitari Vall d'Hebron-Departamento de Oncologia- VHIO ( Site 0300)","08035",[368],{"name":162,"role":163,"phone":369},"+349325434528607",{"lat":371,"lon":372},41.38879,2.15899,{"facility":374,"status":8,"city":338,"zip":375,"country":328,"contacts":376,"geoPoint":379},"Hospital Universitario Fundación Jiménez Díaz-START Madrid-FJD ( Site 0303)","28040",[377],{"name":162,"role":163,"phone":378},"34915504800 x2805",{"lat":351,"lon":352},{"facility":381,"status":8,"city":338,"zip":382,"country":328,"contacts":383,"geoPoint":386},"Hospital Universitario 12 de Octubre ( Site 0304)","28041",[384],{"name":162,"role":163,"phone":385},"+34913908626",{"lat":351,"lon":352},{"facility":388,"status":8,"city":389,"zip":390,"country":328,"contacts":391,"geoPoint":394},"Hospital Universitario Virgen de la Victoria ( Site 0306)","Málaga","29010",[392],{"name":162,"role":163,"phone":393},"+34951032508",{"lat":395,"lon":396},36.72016,-4.42034,{"facility":398,"status":8,"city":399,"state":400,"zip":401,"country":402,"contacts":403,"geoPoint":406},"University Hospitals Sussex NHS Foundation Trust ( Site 0404)","Brighton","East Sussex","BN2 1ES","United Kingdom",[404],{"name":162,"role":163,"phone":405},"+44 01273 696 955",{"lat":407,"lon":408},50.82838,-0.13947,{"facility":410,"status":8,"city":411,"state":412,"zip":413,"country":402,"contacts":414,"geoPoint":417},"Royal Marsden Hospital ( Site 0402)","Fulham","England","SW3 6JJ",[415],{"name":162,"role":163,"phone":416},"+442078118084",{"lat":418,"lon":419},51.48026,-0.1993,{"facility":421,"status":8,"city":422,"state":412,"zip":423,"country":402,"contacts":424,"geoPoint":426},"The Royal Marsden NHS Foundation Trust. ( Site 0403)","Sutton","SM2 5PT",[425],{"name":162,"role":163,"phone":416},{"lat":427,"lon":428},51.35,-0.2,{"facility":430,"status":8,"city":431,"state":432,"zip":433,"country":402,"contacts":434,"geoPoint":437},"Barts Health NHS Trust ( Site 0401)","London","London, City of","E1 1RD",[435],{"name":162,"role":163,"phone":436},"020 7377 7000",{"lat":438,"lon":439},51.50853,-0.12574,{"facility":441,"status":8,"city":431,"state":432,"zip":442,"country":402,"contacts":443,"geoPoint":446},"Guy s & St Thomas NHS Foundation Trust ( Site 0400)","SE1 3SS",[444],{"name":162,"role":163,"phone":445},"+44 020 7188 7188",{"lat":438,"lon":439},{"facility":448,"status":8,"city":449,"zip":450,"country":402,"contacts":451,"geoPoint":454},"The Christie NHS Foundation Trust ( Site 0405)","Manchester","M20 4BX",[452],{"name":162,"role":163,"phone":453},"+441619187689",{"lat":455,"lon":456},53.48095,-2.23743,[458],{"name":459,"role":163,"phone":460,"email":461},"Toll Free Number","1-888-577-8839","Trialsites@msd.com",[463],{"name":464,"affiliation":13,"role":465},"Medical Director","STUDY_DIRECTOR",[],[468],{"label":469,"url":470},"Merck Clinical Trials Information","http:\u002F\u002Fwww.merckclinicaltrials.com",{"nct_id":4,"conditions":472,"biomarkers":476},[473,474,475],"Fallopian Tube Carcinoma","Malignant Ovarian Neoplasm","Primary Peritoneal Cancer",[],{"nct_id":4,"found":478,"summary":479,"prompt_version":489},true,{"design":480,"status":481,"heading":482,"summary":483,"follow_up":484,"word_count":485,"commitments":486,"compensation":487,"drugs_mentioned":488},"This is an interventional study with an estimated enrollment of 460 participants. It has two parts: a dose escalation phase and an expansion phase.","completed","A Study of Raludotatug Deruxtecan for Recurrent Ovarian Cancer","This study is looking for new ways to treat high-grade serous ovarian cancer, primary peritoneal cancer, or fallopian tube cancer that has come back (recurrent). Researchers are testing a study treatment called Raludotatug Deruxtecan (R-DXd), which is an antibody drug conjugate (ADC). You might also receive standard treatments like Carboplatin, Paclitaxel, or Bevacizumab. The study aims to understand the side effects of R-DXd and how many people experience them, as well as how many people need to stop treatment due to side effects. You may be able to join if you are an adult woman with a confirmed diagnosis of these cancers, have measurable disease, and your cancer has returned after 1 to 3 previous treatments.","Participants will be monitored for adverse events for up to approximately 3 years.",116,"Not specified in the trial record.","Not stated in the trial record.",[32,48,53,56],"v2"]